Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs).

e20106Background: Avelumab (MSB0010718C) is a fully human, IgG1 anti-PD-L1 ab under clinical development. We report safety and clinical activity in patients (pts) with relapsed TETs enrolled in a p...